MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202
News Dec 06, 2012
MorphoSys AG has announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202.
The new patent (US 8,263,746) covers functional properties of anti-CD38 antibodies and provides additional patent protection for MorphoSys's HuCAL antibody MOR202.
The newly issued patent adds to the US patent granted earlier this year covering the antibody's protein sequence as well as pharmaceutical compositions comprising the same.
Together, the two patent families provide strong intellectual property protection for the MOR202 program.
The new patent has a scheduled expiry date in 2025, not including any potential patent office or regulatory extensions.
Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: "Antibodies targeting CD38 are gathering increased interest from the pharmaceutical industry as a new potential treatment option in multiple myeloma and other forms of leukemia. As with our other proprietary programs, our goal is to build a rich scientific, medical and commercial package around MOR202 in order to lay the groundwork for future partnering. This new patent widens the scope of our patent position around the MOR202 program by covering the functional aspects of anti-CD38 antibodies in addition to protecting the individual antibody sequence."
MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma and certain forms of leukemia.
The fully human HuCAL-antibody is currently being tested in a phase 1/2a trial in patients with relapsed/refractory multiple myeloma.
Regulatory T Cells Play Essential Role in Hair GrowthNews
UCSF researchers have shown that faulty immune cells may play a role in the development of Alopecia and other forms of baldness.
RNA Molecule that Shields Breast Cancer Stem Cells from Immune System IdentifiedNews
Researchers from Princeton University’s Department of Molecular Biology have identified a small RNA molecule that helps maintain the activity of stem cells in both healthy and cancerous breast tissue.READ MORE
Chance of Colon Cancer Recurrence Nearly Cut in Half in People Who Eat NutsNews
An observational study of 826 patients with stage III colon cancer showed that those who consumed two ounces or more of nuts per week had a 42% lower chance of cancer recurrence and 57% lower chance of death than those who did not eat nuts.READ MORE